From the publishers of JADPRO

Metastatic HER2-Positive Breast Cancer Resource Center


Pertuzumab plus trastuzumab with or without chemotherapy followed by emtansine in ERBB2-positive metastatic breast cancer

Last Updated: Monday, October 16, 2023

Data from a secondary analysis of a phase 2 trial found similar 24-month overall survival rates among patients with HER2-positive locally advanced or metastatic breast cancer who received first-line trastuzumab plus pertuzumab (T+P; 79.0% [90% CI: 71.4%-85.4%]) and for patients who received T+P and chemotherapy (78.1% [90% CI: 70.4%-84.5%]). Median PFS was longer in the chemotherapy group (23.3 months [95% CI: 18.9-33.1]) compared with the non-chemotherapy group (8.4 months [95% CI: 7.9-12.0]). OS and PFS did not markedly differ between populations with ERBB2-enriched and ERBB2-nonenriched cancer.

JAMA Oncology
News & Literature Highlights

Nature Reviews Drug Discovery

Targeting HER2-positive breast cancer: advances and future directions

ESMO Congress 2022 Abstract

Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial

ESMO Congress 2022 Abstract

Clinical safety and pharmacokinetics (PK) data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2-positive metastatic breast cancer

ESMO Congress 2022 Abstract

Quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab-deruxtecan

Cancer Network

Early efficacy observed with trastuzumab deruxtecan ± pertuzumab for HER2+ metastatic breast cancer

Oncology Nursing News

DESTINY-Breast02 confirms benefit of trastuzumab deruxtecan in previously treated patients with HER2+ metastatic breast cancer

Targeted Oncology

Safety of tucatinib triplet for HER2+ breast cancer sealed in real-world analysis

The ASCO Post

T-DXd confirmed as preferred second-line therapy for metastatic HER2-positive breast cancer

Clinical Breast Cancer

A phase II single-arm study of palbociclib in patients with HER2-positive breast cancer with brain metastases and analysis of ctDNA in patients with active brain metastases

Frontiers in Oncology

Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review